A curated exchange of mechanism-targeted candidate intelligence, built on a research program that turns genomic and peptide-sequence analysis into candidate assets — one robust polyketide lead, a peptide-candidate portfolio in development. Every candidate is computational; results are reported against null controls, with no compound yet isolated, characterised, or tested.
Everything below is computational and pending wet-lab — no disease or efficacy claims. Pick the door that fits; the deeper detail (assets, methodology) is available under NDA.
Validation-tiered candidate intelligence; novel-composition leads licensable under NDA; 505(b)(2)/orphan-aware framing.
Licensing & the Exchange →Free, honest-science teaching packages (L0–L3) — real case studies, clearly labelled “not an efficacy grade.” Academic research & education use is free; escalate to a commercial license → when the work goes commercial (spin-out / product / industry partner) — academic-spin-out rates available.
Open academic access →Tox-filtered, trial-whitespace-mapped candidate intelligence — computational, pending wet-lab, no efficacy claims.
Browse the Exchange →Cross-kingdom validation across seven medicinal Basidiomycete and Ascomycete genomes. Every candidate tested against compositional and intergenic null distributions before reporting. Architectural-class and computational evidence only — no pharmacological claims; no compound has been isolated, characterised, or tested. The peptide-candidate portfolio is at the computational-candidate stage with provisional intellectual-property filings.
OmniRayn Discovery advances every asset along one path — computational identification, multi-null validation, structural prediction, then partner-funded wet-lab confirmation. Each asset is shown at the stage it has actually reached. Every asset is produced in-house by a proprietary discovery capability OmniRayn retains; we license assets, not infrastructure.
Architectural-class and computational evidence only. No compound has been isolated, characterised, or tested. Asset-level diligence detail is available to qualified partners under NDA.
Most BGC ranking pipelines distinguish only between “real DNA” and shuffled DNA. We add a second layer that distinguishes BGCs from random non-BGC regions of the same organism's own genome. Most candidates fail the second layer. The ones that survive are the ones we report.
A compositional null (dinucleotide-preserving shuffle) tests whether a candidate looks like real genomic sequence at all. An intergenic null (in-distribution windows from the same organism) tests whether the embedding distance actually separates BGCs from random non-BGC genome of the same organism. Most pipelines skip the second; we run both, every candidate, every time.
Each candidate locus passes through a 7-billion-parameter nucleotide foundation model and is embedded into a high-dimensional pattern space. We do not truncate or PCA-reduce. Why: biosynthetic signal is carried in part by the tail of the hidden state — practitioner truncation to 256 or 512 dims loses information that materially changes the candidate ranking.
Architectural features align with the statin family. We make no claim about pharmacological behavior or compound chemistry — no compound has been isolated, characterised, or tested. The result is a genomic architecture finding, not a drug claim. Full per-cluster detail is in the manuscript currently in submission.
Reviewer copy with deeper detail available under NDA — research@omnirayn.com
Most genome-mining tools keep only candidates that match a known chemical class and quietly discard the rest. We retain and label every candidate the analysis surfaces — including novel-scaffold candidates with no known analog, often the richest source of genuinely new chemistry — then turn the strongest into synthesis- and assay-ready design packages, each labelled with exactly how much is grounded versus hypothesis.
Every candidate is retained and labelled, not discarded for failing to match a known class. The novel-scaffold set — candidates with no known analog — is treated as first-class output, not noise.
From a bare scaffold to a wet-lab-ready package: predicted structure, optimized variants, a developability profile, and a falsifiable hypothesis with explicit pass/fail acceptance criteria and a ready assay plan.
Every result is tiered — well-characterized, class-level, or novel — so you always know how much of a candidate is grounded in known biology versus advanced as a hypothesis to test.
Each result ships with a verifiable provenance attestation — an integrity-and-timestamp record plus public-source citations — so your teams can confirm what was done and when, while the underlying methods stay protected.
Output is organized by type and labelled by confidence — never presented as experimental evidence. This is what a candidate looks like when it leaves the platform.
Every output above is computational. “Confidence” describes how well-grounded a prediction is — not experimental confirmation. Wet-lab validation is the next-stage step.
FirstRayn Biotics is OmniRayn’s product line of directed-fermentation outputs with reproducible recreation protocols and mechanism-anchored biotic indication-discovery dossiers. One deliverable, three partner shapes: botanical drug co-development, fermentation ingredient, and food-grade enzyme × substrate pairings. The flagship is the Lentinula edodes shiitake-derived four-component formulation filed as Shiitake-Bridge; the line expands from there.
Lentinula edodes BGC paired with three established functional ingredients. Four-component formulation; DSHEA pathway.
Pair + hypothesis, recreation protocol, and mechanism anchoring in one package. Pre-registered validation state on every claim.
Botanical drug co-development, fermentation ingredient, food-grade enzyme × substrate pair.
DSHEA for the flagship; FDA Botanical Drug Guidance for co-development; GRAS / NDI / Food Ingredient for the ingredient supply track. See posture →
Brand bridging note. Commercial brand is FirstRayn Biotics; the corresponding intellectual-property filing for the flagship is held under the prior internal name Shiitake-Bridge. All commercial assets reference the FirstRayn Biotics brand; the IP record stays at the filed name. Filing status is disclosed to qualified reviewers under NDA.
Three parallel US pathways apply to the biotics line, depending on what we are selling and what we are claiming. The determining factor is intended use + claim, never the source of the ingredient. All public claims on this surface stay in the structure-function and mechanism-anchoring lane; disease language stays off every surface the engine ships.
For the Shiitake-Bridge flagship and anything sold as a finished dietary supplement. Must contain a dietary ingredient (herb, botanical, extract, concentrate, metabolite, amino acid). Structure-function claims permitted with the mandatory FDA disclaimer. Any dietary ingredient not marketed in the US before 15 October 1994 files a New Dietary Ingredient (NDI) notification 75 days before launch. Disease claims trigger drug classification.
For partners pursuing a multi-component botanical as a drug under IND. Requires CMC reproducibility across multi-component outputs, non-clinical safety, Phase 1 / 2 / 3, and NDA. Only two approved to date: Veregen (2006), crofelemer / Fulyzaq (2012). Reproducibility and standardization of a multi-component extract is the hard part — exactly what directed fermentation addresses.
For the fermentation-ingredient track where OmniRayn Biotics sells ingredient inputs to food, beverage, or supplement brands rather than finished supplements. GRAS self-affirmation + FDA notification, or Food Additive Petition. An ingredient path is independent of a finished product’s path — a supplier can qualify before the downstream brand picks its lane.
International overlay. Market-specific pathways cascade on top of the US path: EU Novel Food Regulation (2015/2283) and Traditional Herbal Medicinal Products Directive (2004/24/EC); Health Canada Natural Health Products Regulations (NHPR); Australia TGA Listed / Registered medicines; China NMPA; India FSSAI; Japan FOSHU. Partnership scoping names the target jurisdictions at the inquiry stage.
Research intelligence posture. Not legal or regulatory advice. Pathway selection stays an operator + counsel decision; the engine supports it with reproducibility and mechanism anchoring, never a claim.
Mechanism-anchored, tox-filtered, trial-whitespace-mapped molecular candidates — every listing carries a validation-state badge so the trust line is never blurred. Research intelligence, computational and pending wet-lab; no disease or efficacy claims. Engagements run under NDA.
Computational transcriptomic prediction, pending wet-lab. The engine’s default output.
Mechanism-level signal confirmed in an assay panel. Not an efficacy or disease endpoint.
Advanced candidate — typically a novel-composition analog with a provisional filed. Structure under NDA.
Validation-state and confidence tier are two different axes — don’t conflate them. Validation-state (Hypothesis → In-vitro validated → Lead) describes whether a candidate has been tested in a wet lab. Confidence tier (Grounded · Class-level · Novel) describes how well-grounded the underlying computational signal is. A candidate can be Class-level in confidence yet still at Hypothesis validation-state — the biology is well-understood, but that specific candidate hasn’t been assayed.
The current catalog is at Hypothesis validation-state. In-vitro and Lead tiers populate as wet-lab data is acquired through partner co-validation.
Real LINCS L1000 compounds ranked by cytotox-corrected selective upregulation of a mitochondrial-function gene set. Tox-clean gate applied; cross-referenced against the trials registry.
A propolis-derived natural product flagged as a selective aging-program reverser, clinically untried. Supplement-lane eligible under structure-function framing — substantiation first, never disease claims.
Full dossier intelligence for non-commercial research. Institutional verification → academic-licensed PDF.
Commercial-use license to the full dossier — a single candidate dossier, or a mechanism bundle.
Exclusive / non-exclusive novel-composition rights. Structure under NDA; Foundry retains title.
A custom computational discovery run on an organism or compound you choose — foundation-model mining (or connectivity screen) with orthogonal null-control validation, delivered as a prioritized candidate package with falsification design. Computational, pending wet-lab; NDA-gated. Larger runs & programs quoted to scope.
Pricing is provided under inquiry. Novel-composition structures are NDA-gated and never shown publicly. Confidential mechanisms are not listed on public surfaces.
Browse 160 mechanism-anchored, tox-filtered, clinical-trial-whitespace-mapped candidate dossiers across 20 compounds — or whole-compound bundles ($3,950). Each is a computational hypothesis, pending wet-lab — structure-function intelligence on a known compound, not medical, efficacy, or freedom-to-operate advice. Delivered as a branded PDF to your email.
All dossiers are commercial-use licensed — $2,450 / dossier, $3,950 / bundle. Academic research & education use is free via the teaching packages; escalate to commercial anytime. Enterprise & catalog licensing scoped on qualification.
160 dossiers · 20 compounds · live catalog · secure Stripe checkout · emailed within minutes
The OmniRayn Discovery methodology paper documents the two-channel null-control validation framework and the biosynthetic-gene-cluster discovery results, at architectural-class level. Full per-cluster detail and methodology internals are available to qualified reviewers under NDA.
Biosynthetic gene cluster discovery has historically ranked candidates against shuffled-sequence controls alone. We document a two-channel null-control framework that adds an intergenic null — random non-BGC regions of the organism's own genome — and apply it across seven medicinal Basidiomycete and Ascomycete genomes.
Class-level empirical results: 131 candidate clusters across seven genomes, with one robust Type I polyketide candidate surviving every null control applied. Architectural-class evidence only — no compound has been isolated, characterised, or tested. Research-stage; methodology preprint forthcoming.
Authors: OmniRayn Discovery Research
Status: Peer-review paper, research-stage. Full text with methodological detail is provided to qualified reviewers under NDA — research@omnirayn.com.
OmniRayn Discovery technology and assets are protected under one or more intellectual-property filings. Filing status, application numbers, and continuation strategy are not disclosed in marketing material and are available to qualified reviewers under NDA.
Trademarks: OmniRayn, OmniRayn Discovery, and FirstRayn Biotics.
All conversations run under NDA. We respond within one business day.
Confidentiality is mutual. Customer data — genomic material, peptide sequences, and pre-publication assemblies for Discovery — is handled under written NDA. Proprietary strains and unpublished candidate sets are never included in training datasets or external reference releases.